Nuvectis Pharma, Inc. Stock Analysis & AI Score
Nuvectis Pharma, Inc. (NVCT) has an ST Score of 38.2 (C), driven by its Momentum (B+) and held back by its Profitability (F). Analysts rate it Buy with a $37.33 price target (+72.6% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Nuvectis Pharma, Inc. (NVCT) has an ST Score of 38.2 (C), driven by its Momentum (B+) and held back by its Profitability (F). Analysts rate it Buy with a $37.33 price target (+72.6% upside).
- Strongest
- MomentumB+
- Weakest
- ProfitabilityF
All factor grades
- MomentumB+
- ForecastB+
- ValuationB-
- Financial StrengthC
- GrowthD
- ProfitabilityF
- Piotroski1/9
Contact
NVCT stock: frequently asked questions
What is NVCT's ST Score?
Nuvectis Pharma, Inc. (NVCT) has an ST Score of 38.2 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is NVCT a buy, hold, or sell?
Analysts rate NVCT a Buy, with a price target of $37.33 (+72.6% vs the current price). Our ST Score grades it C (38.2/100). The ST Score is a data-driven signal, not a recommendation.
What are NVCT's factor grades?
Valuation B-, Profitability F, Financial Strength C, Momentum B+, Growth D, Forecast B+.
What is NVCT's valuation grade?
Nuvectis Pharma, Inc. (NVCT) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is NVCT's growth grade?
Nuvectis Pharma, Inc. (NVCT) earns a growth grade of D, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is NVCT's profitability grade?
Nuvectis Pharma, Inc. (NVCT) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is NVCT's financial strength grade?
Nuvectis Pharma, Inc. (NVCT) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for NVCT?
The average analyst price target for Nuvectis Pharma, Inc. (NVCT) is $37.33 from 3 analysts, which is +72.6% versus the recent price of $21.63.
What is NVCT's Piotroski score?
Nuvectis Pharma, Inc. (NVCT) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.